Phase II study to assess QBECO SSI Efficacy in the Treatment of Colorectal Cancer That Has Spread to the Liver (PERIOP-06)

PERIOP-06 is a phase II study that will assess the efficacy of a medicinal product known as a Site Specific Immunomodulator (SSI) in patients who have planned to undergo surgery to remove colorectal cancer that has spread to the liver (metastases). The SSI under investigation, called QBECO, is designed to restore normal immune function in the gastrointestinal tract and related organs, including the liver, to clear and prevent cancer.  

The primary objective of the PERIOP-06 trial is to assess whether giving the QBECO SSI to patients with metastatic CRC before and after their colorectal surgery can lower their chances of cancer progression.   The goal of this study is to find out if this approach is better or worse than the standard of care. The standard of care is defined as care most people get for metastatic CRC. There is currently no standard of care drug being given before or after surgery to prevent further spread of your cancer. Learn more about this study in the video below.  

In Canada, this study will take place in two participating hospitals in Ontario: 

 

Toronto, Ontario 

Sunnybrook Health Science Centre  

Principal Investigator: Dr. Paul Karanicolas 

Actively recruiting 

Contact:Grace Xu, grace.xu@sri.utoronto.ca

 

Ottawa, Ontario 

Ottawa Hospital Research Institute 

Principal Investigator: Dr. Rebecca Auer 

Actively Recruiting 

Contact: Rose LeClerc, roleclerc@ohri.ca 

 

For more information on this trial: https://clinicaltrials.gov/study/NCT05677113?intr=qbeco%20ssi&rank=3